Piperazine Citrate Anhydrous

Summary

Piperazine Citrate Anhydrous (CHEMBL3990694) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 642.7 Da · C24H46N6O14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3990694
Name	Piperazine Citrate Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	15595021
Molecular formula	C24H46N6O14
Molecular weight	642.7
InChIKey	JDDHUROHDHPVIO-UHFFFAOYSA-N

SMILES: C1CNCCN1.C1CNCCN1.C1CNCCN1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

IUPAC name: bis(2-hydroxypropane-1,2,3-tricarboxylic acid);piperazine

Parent form; salt/anhydrous children: CHEMBL3989678

Patent coverage: 450 distinct patent families (1,189 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).